FieldStrength. Leuven research is finetuning. whole body staging

Similar documents
Emerging Referral Patterns for Whole-Body Diffusion Weighted Imaging (WB-DWI) in an Oncology Center

Fast and easy diagnostic imaging from head to toe

Prof. Dr. NAGUI M. ABDELWAHAB,M.D.; MARYSE Y. AWADALLAH, M.D. AYA M. BASSAM, Ms.C.

Staging Colorectal Cancer

Case Reports: Tumor Detection by Diffusion-Weighted MRI and ADC-Mapping with Correlation to PET/CT Results

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.

FDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave

Radiology Pathology Conference

MR neurography allows clear visualization of peripheral nerves

objectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University

Los Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010

PET/CT Frequently Asked Questions

Bone PET/MRI : Diagnostic yield in bone metastases and malignant primitive bone tumors

Optimized. clinical pathway. propels high utilization of PET/MR at Pitié-Salpêtrière Hospital

An excellent fit to expand the imaging center, Prodiva 1.5T

Imaging in gastric cancer

Imaging of bone metastases

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.

F NaF PET/CT in the Evaluation of Skeletal Malignancy

THE ROLE OF CONTEMPORARY IMAGING AND HYBRID METHODS IN THE DIAGNOSIS OF CUTANEOUS MALIGNANT MELANOMA(CMM) AND MERKEL CELL CARCINOMA (MCC)

Nuclear Sciences and Medicine

An Introduction to PET Imaging in Oncology

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors

Disclosure. Acknowledgement. What is the Best Workup for Rectal Cancer Staging: US/MRI/PET? Rectal cancer imaging. None

Ryan Niederkohr, M.D. Slides are not to be reproduced without permission of author

PET-MRI in malignant bone tumours. Lars Stegger Department of Nuclear Medicine University Hospital Münster, Germany

Neck Imaging Reporting and Data System: An Atlas of NI-RADS Categories for Head and Neck Cancer

Publication for the Philips MRI Community. New MultiTransmit technology advances 3.0T imaging

New Visions in PET: Surgical Decision Making and PET/CT

Lymphoma Read with the experts

ABDOMINAL DIFFUSION WEIGHTED MR

Lung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09

Whole Body MRI. Dr. Nina Tunariu. Prostate Cancer recurrence, progression and restaging

Colorectal Cancer and FDG PET/CT

FieldStrength. Tips for abdomen/pelvis oncology imaging. SPECIAL ISSUE MR in oncology. Publication for the Philips MRI Community

PET CT for Staging Lung Cancer

CT PET SCANNING for GIT Malignancies A clinician s perspective

CLINICAL PRESENTATION AND RADIOLOGY QUIZ QUESTION

LYMPHATIC DRAINAGE IN THE HEAD & NECK

MR Tumor Staging for Treatment Decision in Case of Wilms Tumor

Imaging of Neuroendocrine Metastases

PET/CT F-18 FDG. Objectives. Basics of PET/CT Imaging. Objectives. Basic PET imaging

PET/CT in oncology. Positron emission tomography

Nuclear Medicine in Oncology

MRI-PET: Oncologic Applications

Indications of PET/CT in oncology

High spatial resolution reveals excellent detail in pediatric neuro imaging

Thymic Tumors. Feiran Lou MD. MS. Kings County Hospital Department of Surgery

Detection of Soft Tissue Tumors on Bone Scintigraphy: Report of Four Cases

Lung. 10/24/13 Chest X-ray: 2.9 cm mass like density in the inferior lingular segment worrisome for neoplasm. Malignancy cannot be excluded.

PET/CT in breast cancer staging

PET/MR:Techniques, Indications and Applications

Molecular Imaging and Cancer

What Radiologists do?

Radiological staging of lung cancer. Shukri Loutfi,MD,FRCR Consultant Thoracic Radiologist KAMC-Riyadh

Diffusion Weighted Imaging in Pediatric Body: Update

Nuclear medicine in oncology. 1. Diagnosis 2. Therapy

PET/CT in lung cancer

Typical PET Image. Elevated uptake of FDG (related to metabolism) Lung cancer example: But where exactly is it located?

Cancer Program Report 2014

MEASUREMENT OF EFFECT SOLID TUMOR EXAMPLES

Publication for the Philips MRI Community

Learning Objectives. 1. Identify which patients meet criteria for annual lung cancer screening

COLORECTAL CANCER STAGING in 2010

ROLE OF PET-CT IN BREAST CANCER, GUIDELINES AND BEYOND. Prof Jamshed B. Bomanji Institute of Nuclear Medicine UCL Hospitals London

Large health system benefits from multiple scanners for breast MRI

Small Cell Lung Cancer

EDITORIAL. Vien X Nguyen 1, Cuong C Nguyen 1, Ba D Nguyen 2. Mayo Clinic Arizona. Scottsdale, AZ, USA

HEALTHFIRST 2011 RADIOLOGY PROGRAM CODE LIST

Case Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma.

FieldStrength. Multi-parametric 3.0T MRI provides excellent prostate imaging

Abdominal applications of DWI

1/25/13 Right partial nephrectomy followed by completion right radical nephrectomy.

Exercise 15: CSv2 Data Item Coding Instructions ANSWERS

Dr Claire Smith, Consultant Radiologist St James University Hospital Leeds

2004 SNM Mid-Winter Educational Symposium

Oncologic Applications of PET Scanning

Abdomen Sonography Examination Content Outline

Subject: PET Scan With or Without CT Attenuation. Original Effective Date: 11/7/2017. Policy Number: MCR: 610. Revision Date(s): Review Date:

Management of Neck Metastasis from Unknown Primary

Denominator Criteria (Eligible Cases): Patient encounter during the performance period (CPT): 78300, 78305, 78306, 78315, 78320

11/10/2015. Prostate cancer in the U.S. Multi-parametric MRI of Prostate Diagnosis and Treatment Planning. NIH estimates for 2015.

Boot Camp Case Scenarios

Imaging Work-Up of a Neck Mass - Adults & Children

What is head and neck cancer? How is head and neck cancer diagnosed and evaluated? How is head and neck cancer treated?

Liver imaging takes a step forward with Ingenia

POSITRON EMISSION TOMOGRAPHY (PET)

Diffuse high-attenuation within mediastinal lymph nodes on non-enhanced CT scan: Usefulness in the prediction of benignancy

MRI in lymphoma: where are we in 2016

Ingenia 3.0T excels in cardiac imaging

Institution INSTRUCTIONS (M3) - All other imaging studies, including CT, CONVENTIONAL MRI, PET SCINTIGRAPHY, etc... AND

Mediastinal Tumors: Imaging

Imaging Decisions Start Here SM

Role of imaging in RCC. Ultrasonography. Solid lesion. Cystic RCC. Solid RCC 31/08/60. From Diagnosis to Treatment: the Radiologist Perspective

Imaging Features of Sarcoidosis on MDCT, FDG PET, and PET/CT

Dr Sneha Shah Tata Memorial Hospital, Mumbai.

Lung Cancer-a primer. Sai Yendamuri, MD Professor and Chair, Dept of Thoracic Surgery,RPCI,Buffalo

Positron Emission Tomography in Lung Cancer

Fusion Ultrasound: Characterization of Abdominal Masses with MR, CT, PET, and Contrast Ultrasound

primary (CUP) syndrome

Transcription:

FieldStrength Publication for the Philips MRI Community Issue 40 May 2010 Leuven research is finetuning 3.0T DWIBS for whole body staging The University Hospital of Leuven is researching 3.0T whole body diffusion-weighted MRI for single-step cancer staging This article is part of Field Strength issue 40, May 2010

Leuven research is fine-tuning 3.0T DWIBS for whole body staging The University Hospital of Leuven is researching 3.0T whole body diffusion-weighted MRI for single-step cancer staging For several years, radiologist Dr. Vincent Vandecaveye and his colleagues at the University Hospital Leuven (Belgium) have been assessing the value of 3.0T DWIBS in staging of suspicious lesions according to TNM (Tumor, Node, Metastasis) method in a single scan. Working with an Achieva 3.0T system, and more recently with a new Achieva 3.0T TX system with Philips MultiTransmit technology, the Leuven team is achieving very promising results. Vincent Vandecaveye, MD, is radiologist at University Hospitals Leuven, Belgium. He is involved in different projects evaluating the use of diffusion- and perfusion-weighted MRI in oncology. Thanks to its exceptional contrast-to-noise ratio and the resulting improved lesion conspicuity, diffusion-weighted MR imaging (DWI) offers additional value to conventional MRI for lesion visualization. The benefits of the technique are even more apparent at 3.0T, which enables even higher contrast-to-noise ratios. This has encouraged clinicians at the University Hospital Leuven to explore the advantages of 3.0T DWIBS (whole body diffusion weighted imaging) in singlestep cancer staging. University Hospital Leuven 3.0T DWIBS can provide fast visualization of suspicious lesions Currently, after an initial diagnosis of primary cancer, routine staging is performed on modalities such as CT, FDG-PET/(CT) and bone scintigraphy, while MRI is often performed for problemsolving or loco-regional staging. Diffusion weighted MRI (DWI) is currently not commonly used for whole body staging because of the relative immaturity of DWI applications and the time it takes to fully evaluate lesions using ADC mapping. This is not the case with loco-regional DWI, where fewer lesions need to be evaluated, making ADC-calculation less time consuming, and multiple b-values can be used for ADC-calculation to assist in accurate lesion characterization. However, such a time investment should be avoided in whole body staging where finding suspicious lesions is really the aim, says Dr. Vandecaveye. For this purpose, we accept some loss in resolution and reduce the number of b-values to only b0 and b1000. We also try to reduce the number of lesions that require ADC calculation for characterization. Even though some resolution is lost when going from localized to whole-body DWI, we re still able to see very small lesions down to 4 mm. The challenge is to be able to assess from a single whole body scan whether lesions need follow-up or not. 6 FieldStrength Issue 40 May 2010

CT DWI DWI Lung tumor and metastatic lesion Patient with lumbar pain and left radicular pain. CT of the lumbar spine shows an osteolytic lesion in the lumbar body L4 (rectangle). Subsequent whole body DWI confirms the metastatic lesion as a hyperintense lesion (arrow). Additionally, WB-DWI shows a b1000 hyperintense mass in the left lung, compatible with a primary lung tumor. This was confirmed by subsequent CT of the chest and bronchoscopy. Images provided by Dr. Pans, UHL. MultiTransmit reduces imaging time The Leuven team used their experience in regional 3.0T DWI to develop their whole body staging protocol primarily based on DWIBS for quickly assessing the level of secondary lesions in patients with a primary tumor diagnosis. The examination, which takes only 20 minutes on the Achieva 3.0T TX with MultiTransmit comprises a fast whole-body anatomical scan (which serves for DWIBS planning) and a single free-breathing whole-body DWI scan at b-values of 0 and 1000, optimized for visualizing lymph node, liver and skeletal/soft-tissue lesions. I must say that we are impressed with the new Achieva TX system in this application. Thanks to the MultiTransmit technology, the anatomical sequences have really shortened, reducing their imaging time tremendously. So if we need immediate anatomical correlation for the imaging findings of DWIBS, the addition of co-registered whole body T1- or T2-sequences does not greatly increase total examination time, points out Dr. Vandecaveye. We also see advantages in image quality in particular the B1 artifact which sometimes shows up as shading in 3.0T images appears to be much reduced in whole-body imaging, thanks to MultiTransmit. Even though some resolution is lost when going to whole-body DWI, we are still able to detect very small lesions down to 4 mm. FieldStrength 7

PET CT DWI Suspected neuro-endocrine tumor Patient presenting with increased chromogranine tumor marker, suspect of neuro-endocrine tumor (NET). DOTATOC PET and co-registered CT show a metastatic lesion in the left thoracic inlet (arrow) and a tumoral mass in the mesenterium (rectangle). Whole body diffusion-weighted MRI confirms the presence of the thoracic metastatic mass (arrow) and mesenterial mass (rectangle). Additional small peritoneal metastases are depicted as b1000 hyperintense lesions over the liver dome and right lateral hypochondriac area (arrowheads). Lesions were confirmed during imaging follow-up. FDG-PET CT DWI With MultiTransmit, the anatomical sequences have really shortened, reducing their imaging time tremendously. Recurrent cutaneous melanoma Patient with recurrent cutaneous melanoma. FDG-PET shows a hypermetabolic focus in the right axilla, compatible with a metastatic adenopathy (arrowhead), as well as a subcutaneous metastasis in the right gluteal area (arrow). Co-registered CT in the lung window shows the presence of multiple lung metastases (circles). WB-DWI clearly shows the metastatic mass in the right axilla as a b1000 hyperintense area (arrowhead), corresponding to an ADC of 0.00073 mm 2 /s, two subcutaneous metastases as b1000 hyperintense nodules in the right gluteal muscle (arrows) and multiple lung metastases, also depicted as b1000 hyperintense lesions (circles). Images provided by Dr. Pans, UHL. 8 FieldStrength Issue 40 May 2010

Lymphoma treatment response Before treatment CT After treatment CT Patient with lymphoma localization in the right iliac wing. The CT-scan two weeks after start of chemotherapy shows no different volume of the mass. FDG-PET shows a significant decrease of FDG-uptake, while WB-DWI shows significant decrease of b1000 signal intensity, correlating to a significant increase in ADC. Both findings indicate good tumor response. Two year follow-up in the PET PET patient revealed no tumor recurrence. DWI DWI Although whole body DWIBS will not be a replacement for other techniques like FDG- PET or CT, we fully expect it to offer additional value. Dr. Vandecaveye believes this relatively short examination protocol may be a valuable approach for imaging oncology patients. The Leuven center is currently studying this method in a group of patients that have common carcinogenic risk caused by the use of alcohol and tobacco, which is known to have an increased risk of head/neck, lung, esophageal and to lesser extent colorectal cancer. Additionally, they are investigating DWIBS for patients with lymphoma and neuro-endocrine tumors. Image interpretation requires experience Since interpreting the results requires considerable experience, Dr. Vandecaveye is developing a set of criteria for fast interpretation. For hepatic metastases, our study currently looks at high signal intensities on the b1000 image and the ADC. Although we find that the b1000 image is often sufficient for diagnostic use, the ADC still offers additional value for exclusion of the T2-shine through effect in hemangiomas and cysts. As the improved signal on 3.0T field strength allows us to increase b-values to 2000, this may further help to differentiate liver metastases based on the high b-value. For skeletal and soft tissue lesions, it does not appear that the ADC map provides additional information to the b1000 image. However, for evaluating lymph nodes the ADC maps are important because signal intensity differences are small on the b1000 images. Apart from suspicious lesions, other anatomies also give high signal intensities on b1000 DWI images, including the brain, the spleen and kidneys, nerve roots from the lumbar and thoracic spine, and salivary and reproductive glands. It s therefore important for radiologists to be aware of these areas and to know how they appear on diffusion weighted images to avoid pitfalls when interpreting the exam. Further plans for using DWIBS What we plan to do next is to define in which patients DWIBS may be useful for staging. And most important, we must clearly identify the weaknesses of the technique including false positives and negatives. When we know these, we should be in a position to know when and how to use the protocol, not only for staging, but also for diagnosing and assessing early response to treatment. We can then establish how we can deploy it to complement FDG-PET or CT. Although whole body DWIBS will not be a replacement for these techniques, we fully expect it to offer additional value, both for diagnosis and treatment follow-up. FieldStrength 9